Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 3, 2019
Daily News
December 3, 2019
- Average NHI-Market Price Gap at “Around 8%”, MHLW Reveals to LDP Bigwigs; Total Savings Undisclosed
December 3, 2019
- Ryukaikon’s Dec. 9 Meeting Likely to Be Put Off in Wake of Bid-Rigging Scandal
December 3, 2019
- Lenvima’s Add’l Thyroid Cancer Use Accepted for Chinese Regulatory Review
December 3, 2019
- Zykadia’s Film-Coated Tablets Now Available
December 3, 2019
- Full Showdown Starts as Mylan’s Nesp Biosimilar Reaches Market
December 3, 2019
- Crysvita’s Japan Launch Set for Dec. 6: Kyowa Kirin
December 3, 2019
- Chugai Completes Transfer of 3 Dermatology Products to Maruho
December 3, 2019
- Astellas to Buy Gene Therapy Player Audentes for US$3 Billion
December 3, 2019
- Shionogi Introduces AI Chatbot for Xofluza Inquiries from Medical Professionals
December 3, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…